Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology. 

Congress has already adjourned for the year without taking action, but U.S. medical societies are hoping relief from significant Medicare cuts will arrive in early 2024. 

The company and one of its subsidiaries would allegedly confuse clinicians and have them bill government programs for cardiac monitoring services that were more expensive than what they needed. This settlement resolves those allegations. 

RBMA President-elect Pete Moffatt discusses how to contend with challenges such as staff shortages and reimbursement issues.

Richard Heller, MD, a member of the RSNA Board and associate CMO for Rad Partners, explains the impact of the 2024 Medicare cuts and what is at stake.

The alleged scheme involved a series of diagnostic procedures that, according to the U.S. government, were not medically necessary. 

The policies cover a wide range of interventional therapies, including Shockwave Medical's IVL technology and intravascular ultrasound. 

RBMA President Kit Crancer said continued cuts will result in Medicare patients losing access to care when health systems and providers determine it is no longer economical.